• Okadaic acid (A4540): Technical Guidance for PP1/PP2A Inhibi

  2026-06-10

  Okadaic acid is a high-potency inhibitor of serine/threonine protein phosphatases PP1 and PP2A, enabling precise control of phosphorylation-dependent signaling, apoptosis assays, and signal transduction workflows. It is best applied in controlled biochemical or cell biology experiments requiring robust, selective phosphatase inhibition. Systems sensitive to solvent effects or requiring non-overlapping phosphatase specificity should avoid its use.

• Lipid Scrambling Suppresses Ferroptosis and Boosts Tumor Imm

  2026-06-10

  Yang et al. identify TMEM16F-mediated lipid scrambling as a plasma membrane repair mechanism that suppresses the terminal execution of ferroptosis in tumor cells. Inhibiting this process not only sensitizes tumors to ferroptosis but also enhances anti-tumor immune responses, suggesting new strategies for cancer therapy.

• Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Peptide Linker

  2026-06-09

  Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker designed for selective payload release in antibody-drug conjugate (ADC) research. It is optimal for workflows requiring organic solubility and lysosomal cleavage specificity, but it is not suitable for water-based, diagnostic, or therapeutic applications.

• Cholesterol in Lipid Nanoparticle Workflows: Protocols & Sol

  2026-06-09

  Cholesterol, the principal sterol, is integral to state-of-the-art lipid nanoparticle (LNP) systems for mRNA delivery in cancer research. This guide details workflow enhancements and troubleshooting tips for reproducible nanoparticle assembly, drawing on recent bladder cancer studies and leveraging APExBIO’s high-purity cholesterol.

• SLC25A1 Upregulation Drives Cisplatin Resistance via Senesce

  2026-06-08

  Li et al. (2026) demonstrate that upregulation of SLC25A1 confers cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) by promoting cellular senescence through H3K27 acetylation–mediated gene activation. This mechanistic insight highlights SLC25A1 as a predictive biomarker and therapeutic target, providing new directions for overcoming chemoresistance in HNSCC.

• Transmission Dynamics of Carbapenemase Genes in CREC, Guangd

  2026-06-08

  This study systematically investigates the prevalence, genetic location, and dissemination modes of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) from eight teaching hospitals in Guangdong, China (2022–2024). The findings reveal a high frequency of plasmid- and chromosome-borne blaNDM-1, efficient horizontal gene transfer, and a strong association with multidrug resistance, providing critical insights for antibiotic resistance research and surveillance.

• NBC19 and the NLRP3 Inflammasome: Mechanistic Depth & Assay

  2026-06-07

  Explore the mechanistic underpinnings and assay implications of NBC19, a leading NLRP3 inflammasome inhibitor. This article offers a deeper analysis of IL-1β release inhibition, integrating new insights for inflammation research.

• Precision Viability Staining: Nanomaterials, Membranes & Tra

  2026-06-06

  This thought-leadership article explores how mechanistic insight into bacterial membrane integrity, empowered by advanced viability staining protocols, is redefining translational strategies in infectious disease and nanomaterial research. It contextualizes the APExBIO Live-Dead Bacterial Staining Kit within the evolving landscape, referencing pivotal studies in jaw osteomyelitis and providing actionable guidance for translational researchers seeking robust, reproducible viability data.

• Fluorouracil in Solid Tumor Research: Protocols & Innovation

  2026-06-05

  Fluorouracil (Adrucil) from APExBIO stands as a gold-standard reagent for investigating DNA replication inhibition and antitumor efficacy in solid tumor models. This article delivers actionable protocols, advanced troubleshooting, and practical insights tailored to maximize reproducibility and translational impact in colon and breast cancer research.

• Praeruptorin A Suppresses NF-κB and Inflammatory Genes in Ma

  2026-06-05

  This study demonstrates that Praeruptorin A, a coumarin from Peucedanum praeruptorum, inhibits NF-κB activation and the expression of key inflammatory mediators in poly (I:C)-stimulated RAW264.7 macrophages. The findings provide mechanistic insight into the modulation of macrophage-driven inflammation, highlighting the potential of natural products as leads in antiviral and immunomodulatory research.

• Cholesterol Impedes Lipid Nanoparticle Trafficking for Nucle

  2026-06-04

  This study provides critical mechanistic insights into how elevated cholesterol content within lipid nanoparticles (LNPs) hinders their intracellular trafficking and reduces nucleic acid delivery efficiency. By dissecting the roles of LNP components, the paper informs rational design for more effective nonviral delivery systems.

• CCG-1423: Precision RhoA Inhibitor for Cancer and Viral Entr

  2026-06-04

  CCG-1423 stands out as a potent RhoA inhibitor, uniquely targeting MRTF-A/importin α/β1 interactions to modulate both cancer cell behavior and viral entry pathways. This guide explores robust experimental protocols, cross-domain applications, and troubleshooting strategies, empowering researchers to unlock the full potential of CCG-1423 from APExBIO.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Workflow

  2026-06-03

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables specific, sensitive detection of goat IgG in fluorescence-based assays such as ICC/IF, IHC, flow cytometry, and ELISA. It is not designed for non-goat primary antibodies or unsupported assay types. Proper handling and adherence to validated protocols are essential for consistent results.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3

  2026-06-03

  Wu et al. demonstrate that Reticulocalbin 2 (RCN2) promotes metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) through UBR5-mediated degradation of PPP2CA, leading to activation of the PI3K-Akt signaling pathway. Their mechanistic findings offer a compelling rationale for targeting the RCN2-PPP2CA-PI3K-Akt axis to overcome aggressive disease and chemoresistance in ESCC.

• SU6656 Src Tyrosine Kinases Inhibitor: Applied Protocols & O

  2026-06-02

  SU6656, a potent Src tyrosine kinases inhibitor, is driving breakthroughs in both radiotherapy sensitization and scalable platelet production from hiPSCs. This article unpacks stepwise experimental workflows, key innovations, and troubleshooting strategies to maximize SU6656's translational value for cancer and regenerative medicine researchers.

11853 records 3/791 page Previous Next 12345 下5页 Last page